How a mutation a®ects the binding free energy of a ligand is a fundamental problem in molecular biology/biochemistry with many applications in pharmacology and biotechnology, e.g. design of drugs and enzymes. Free energy change due to a mutation can be determined most accurately by performing alchemical free energy calculations in molecular dynamics (MD) simulations. Here we discuss the necessary conditions for success of free energy calculations using toxin peptides that bind to ion channels as examples. We show that preservation of the binding mode is an essential requirement but this condition is not always satis¯ed, especially when the mutation involves a charged residue. Otherwise problems with accuracy of results encountered in mutation of charged residues can be overcome by performing the mutation on the ligand in the binding site and bulk simultaneously and in the same system. The proposed method will be useful in improving the a±nity and selectivity pro¯les of drug leads and enzymes via computational design and protein engineering.
Introduction
During evolution, mutations have played a key role in development of peptides that bind to receptor proteins with high a±nity. Binding of peptide ligands serves mainly useful purposes within the body, e.g. functioning of many membrane proteins requires binding of a speci¯c ligand. However, peptides are also used by venomous animals as toxins to kill their preys, where the toxin usually binds to an ion channel in the nervous system, paralyzing the prey. In molecular biology, high-a±nity peptides are often utilized in site-directed mutagenesis experiments to probe the structure and function of receptor proteins. 1, 2 For example, in the common alanine scanning experiments, each residue on a peptide is mutated to alanine, and the e®ect of the mutation on the binding constant is determined. This provides a map of the residues involved in binding, which facilitates construction of models of proteinligand complexes via computational means, and more importantly their rigorous validation. Complex models, in turn, are helpful in providing a unique interpretation of the mutation data. While mutation experiments are very informative, they are also expensive and time consuming. Thus a more economical approach would be¯rst to identify the residues involved in binding from complex models and calculate the free energy change due to their mutation, and then perform the mutation experiments only for the identi¯ed residues to con¯rm the model predictions. Because the change in the binding free energy of a ligand due to a mutation is typically around a few kcal/mol, viability of such an approach depends on calculation of free energy changes near chemical accuracy.
Peptides that bind to a receptor protein with high a±nity are also used for therapeutic purposes À À À when a protein becomes dysfunctional, causing a disease, its behavior can be modulated via binding of a peptide. [3] [4] [5] [6] [7] [8] Because a peptide that is potent for a target protein often binds to other proteins with high a±nity as well, direct use of a wild-type peptide as a therapeutic agent could lead to undesirable side e®ects. Thus an important problem in drug design from peptides is to improve their selectivity pro¯les for the intended target. This problem can be addressed by¯nding mutations on a peptide which reduce its a±nity to the o®-target proteins while preserving its potency for the target protein. Again¯nding such mutations in the lab by trial and error is not the best strategy. If feasible, computational prediction followed by experimental con¯rmation would be a much more preferable option.
Clearly accurate calculation of free energy change due to a mutation is an important problem in molecular biology/biochemistry with many potential applications in biomedical, pharmaceutical and biotechnological industries. Several methods are available for this purpose from simple docking and scoring, 9, 10 to intermediate molecular mechanics with Poisson-Boltzmann surface area (MM-PBSA), 11 and more sophisticated alchemical free energy calculations. [12] [13] [14] [15] [16] Simple methods such as docking and scoring are very fast but their accuracy for predicting binding a±nities is very limited. 17, 18 MM-PBSA is also a high throughput method and has a relatively better accuracy for binding a±nities compared to docking and scoring but still it is not su±ciently accurate. 19, 20 The most accurate methods for calculating the free energy change due to a mutation are free energy perturbation (FEP) and thermodynamic integration (TI), where a residue on the ligand (or protein) is alchemically transformed to another residue in molecular dynamics (MD) simulations. [21] [22] [23] [24] However, there are several issues that could a®ect the feasibility and accuracy of such FEP/TI calculations. The most critical issue is whether the binding mode is preserved after the mutation or not. 24 If a substantially di®erent binding mode is obtained for the mutated ligand, it is unlikely that the¯nal state will be sampled in relatively short FEP/TI MD runs, leading to an erroneous result. Mutations involving charged residues are also known to cause problems in FEP/TI calculations. These problems may be resolved by performing the mutation on the ligand in the binding site and bulk simultaneously. 25 That is, while the ligand is mutated to an analogue in the binding site, the reverse mutation is performed simultaneously on the analogue in bulk water in the same system. Finally, the force¯eld used in the FEP/ TI calculations could lead to inaccuracies. Thanks to continuous improvements, the current force¯elds such as AMBER, 26 CHARMM 27 and GROMOS, 28 give pretty robust results in binding free energy calculations. [13] [14] [15] [16] Thus this is less of a concern compared to the¯rst two issues.
Here we address the issues in free energy calculations due to mutation of charged residues using the complexes of peptide toxins ShK and HsTx1 with the voltage-gated potassium channels Kv1.1 and Kv1.3 as examples. These systems are chosen because both peptides are high-a±nity blockers of Kv1.3, 29, 30 which is a proven target for treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and type 1 diabetes. [31] [32] [33] [34] Thus ShK and HsTx1 provide valuable leads for immunotherapy. However, they also bind to the Kv1.1 channel with high a±nity, 29, 30 which is in the nervous system and should be avoided. Over the past decade, many analogues of ShK have been constructed in the lab to improve its selectivity for K1.3 over Kv1. 1. 7,36,35 But because they all contain non-natural amino acids or adducts, there is still a need to develop ShK analogues that contain only natural amino acids. Computational methods could be useful in this endeavor, and to this end we constructed complexes of ShK and HsTx1 with the Kv1.x channels. 37, 38 The complex models were validated by comparing the binding free energies determined from potential of mean force (PMF) calculations with the experimental values, and also using the alanine scanning data where available. Several mutations on ShK and HsTx1 were suggested by these models to improve their Kv1.3/Kv1.1 selectivity. In particular, the e®ect of the K18A mutation on the binding free energy of ShK was studied using the FEP, TI and PMF methods, and the predicted gain in selectivity free energy was con¯rmed in subsequent experiments. 25 Another mutation suggested in ShK (R29A), 37 was not pursued because it changed the binding mode. Similarly, the R14A mutation in HsTx1 was predicted to improve the Kv1.3/Kv1.1 selectivity from PMF calculations, which was con¯rmed in experiments. 39 In this study, FEP and TI calculations were not performed because there was some change in the binding mode. Here we investigate in detail the R29A mutation in ShK and the R14A mutation in HsTx1 to examine under which conditions the FEP/TI calculations can be expected to predict the changes in the binding free energies due to mutations.
Methods

Modeling of complex structures and MD simulations
The NMR structures of ShK and HsTx1 are available from the Protein Data Bank (PDB IDs, 1ROO 41 and 1QUZ 42 ). The analogues ShK[R29A] and HsTx1[R14A] are generated from the wild type structures using the Mutator plugin in VMD. 45 MD simulations of the analogues in bulk water indicate that the mutations do not cause any structural changes in the toxins. The structures of Kv1.1 and Kv1.3 channels are constructed from the crystal structure of Kv1.2 (PDB ID, 2R9R 43 ) as described in our earlier work. 37 Stability and integrity of the channel models have been well established in previous studies of binding of ShK and HsTx1 to Kv1 channels. 37, 38 Complex structures of ShK and HsTx1 with the Kv1.x channels are taken from previous work, 37, 38 where the docking program HADDOCK, 40 was used together with MD simulations for re¯nement. Here we follow the same procedure to obtain the complex structures for the analogues ShK[R29A] and HsTx1[R14A] with the Kv1.x channels. First MD simulations are run for each analogue in bulk water for 5 ns and ten conformers are chosen from each simulation. These conformers are used in ensemble docking with HADDOCK to the Kv1.1 and Kv1.3 channels. The pore inserting lysine (K22 in ShK and K23 in HsTx1) and the tyrosine carbonyls in the selectivity¯lter are used as a restraint in the docking. In all cases, a consensus is obtained among the top ten poses, so the pose with the best energy score is chosen for re¯nement with MD. Each complex structure is embedded in a lipid bilayer consisting of 125 POPC molecules and solvated with 10,500 water molecules and 100 mM KCl. After the correct water and lipid densities are obtained with pressure coupling, the x and y dimensions of the simulation box are¯xed and pressure coupling is applied only in the z direction. The protein-toxin complex is then gradually relaxed in 5 ns MD simulations, following the protocols established for Kv1 channels. 44 The equilibrated system is run for a further 20 ns to monitor the convergence of the channel protein and toxin peptide from the RMSD of the backbone atoms. The trajectory data collected are used in analysis of the binding mode of each complex.
In the FEP/TI calculations, the wild type toxin is alchemically transformed to the analogue in the binding site. To check the feasibility of this process, we have also generated the complex structures Kv1.x-ShK[R29A] Ã and Kv1.x-HsTx1[R14A] Ã directly from the wild-type complexes Kv1.x-ShK and Kv1.x-HsTx1 using the Mutator plugin. 45 Here asterisk is used to distinguish between the two complex structures obtained using di®erent methods. As will be discussed in the results, similarity of the two complex structures is essential for the success of the FEP/TI calculations.
MD simulations are performed using the NAMD program, 46 with the CHARMM36 force¯eld. 47 An NpT ensemble is used with the temperature and pressure maintained at 300 K and 1 atm, respectively, via Langevin coupling with damping coe±cients of 5 ps À1 and 10 ps À1 . Periodic boundary conditions are employed together with particle-mesh Ewald algorithm to compute the long-range electrostatic interactions. Lennard-Jones (LJ) interactions are switched o® within a distance of 10-13.5 # A. A time step of 2 fs is used, and the trajectory data are written at 1 ps intervals.
FEP and TI calculations
Performing FEP or TI in MD simulations currently o®er the most accurate methods for calculating the free energy change due to a mutation. [21] [22] [23] [24] To determine the e®ect of a mutation on the binding free energy of a ligand to a protein, one needs to perform two FEP/TI calculations; one in the binding site of the protein and another in bulk water. Traditionally, these calculations have been performed separately because the bulk simulations require a much smaller system. However, this creates two problems for charge mutations. First, the system needs to be kept neutral during annihilation or creation of a charge, which requires introduction of auxiliary ions that are simultaneously transformed, 48 or inclusion of correction terms to compensate for the loss of neutrality. 49 Second, substantial errors could arise from calculation of large solvation energies associated with charges, and these are less likely to cancel out when the binding site and bulk calculations are performed in di®erent systems. These problems can be avoided by increasing the system size slightly and performing the two calculations simultaneously and in the same system. That is, while a charged residue on the toxin is mutated to a neutral one in the binding site, the reverse transformation is applied simultaneously to the mutant toxin in bulk, which is well separated from the binding pocket. Advantages of simultaneous FEP/TI calculations was¯rst demonstrated for binding of Asp to the glutamate transporter GltPh, 50, 51 followed by binding of charged and polar ligands to the glutamate receptor GluA2. 52 A further problem arises in charge mutations when the Coulomb and LJ interactions are switched on or o® simultaneously. This leads to stability and convergence issues in FEP/TI calculations. To resolve this problem, the two interactions need to be handled separately, which can be achieved by introducing residues with uncharged side chains as intermediate steps in FEP/TI calculations. For example, the change in the binding free energy of ShK due to the R29A mutation can be expressed as:
where R 0 and A 0 denote arginine and alanine residues with no partial charges in their side chains. The thermodynamic cycle that combines these procedures in the FEP/ TI calculations is illustrated in Fig. 1 . The binding free energy di®erence between the mutant and the wild type toxin in Eq. (1) is represented by the top and bottom horizontal legs in Fig. 1 . The same free energy can be calculated from the di®erence of the vertical legs in Fig. 1 as indicated in Eq. (2). The¯rst loop in Fig. 1 corresponds to the¯rst bracketed term in Eq. (3) and represents the discharging of the side chain of an Arg residue on the toxin in the binding site while the reverse process is performed on a toxin in bulk with an uncharged Arg side chain. This ensures that the net charge in the system does not change during the FEP/TI calculations. In the second loop, corresponding to the second term in Eq. (3), the uncharged Arg side chain is transformed to an uncharged Ala side chain on the bound toxin while the reverse is performed on the bulk toxin. This step involves only the LJ interactions which are thus decoupled from the Coulomb interactions. Finally in the third loop, corresponding to the third term in Eq. (3), the Ala side chain is charged on the bound toxin while the one in bulk is discharged. Each of the contributions to the free energy di®erence in Eq. (3) can be calculated using the FEP or TI methods. In both methods, one introduces a hybrid Hamiltonian
where H 0 and H 1 represent the Hamiltonian for the initial and¯nal states respectively. In the FEP method, the interval ½0; 1 for is divided into n subintervals with ½ i ; i ¼ 1; . . . ; n À 1, and for each subinterval the free energy di®erence is calculated from the ensemble average
The free energy di®erence between the initial and¯nal states is obtained from the sum, ÁG ¼ P i G i . The i values are chosen such that the free energy change in each step is small enough (e.g. $ 2 kcal/mol) to enable su±cient sampling of the system in a reasonable time frame and ensure convergence of the results. For charge mutations (the¯rst term in Eq. (3)), satisfaction of this condition would require over 130 windows if uniform subintervals are used. We use exponentially spaced subintervals instead to reduce the required number of windows to 66. Each window is equilibrated Fig. 1 . The thermodynamic cycle used in the free energy calculations illustrated for the Arg!Ala mutation. Arg and Ala residues with no partial charges on the side chains are indicated with the superscript 0. Note that the Ala side chain is neutral overall but has small partial charges on C and H atoms. for 80-ps followed by a 240-ps production run, which is double the time used in earlier calculations. 25 For the neutral Ala side chain (the third term in Eq. (3)), using half of these times is found to be su±cient. Each forward calculation is supplemented with a backward calculation to check for hysteresis e®ects. To ensure independence of the two calculations, the¯nal system obtained from the forward transformation is equilibrated for up to 10 ns before starting the backward calculation. For the LJ part (the second term in Eq. (3)), we use 30 equally-spaced windows near the end points, i.e., for between 0-0.3 and 0.7-1 and 20 equally-spaced windows in between. Each window is equilibrated for 20-ps followed by a 30-ps production run. 25 In order to improve convergence and prevent instabilities, a soft-core LJ potential with a shift coe±cient of 7.0 is employed. 53 In the TI method, the free energy di®erence is calculated from the integral
where the ensemble average of the derivative @HðÞ=@ is obtained at several values from MD simulations. For Coulomb interactions, Eq. (6) can be evaluated most e±ciently using Gaussian quadrature with a relatively small number of windows. In previous applications of the TI method, 50 a 7-point quadrature was found to be adequate, which is also adopted here. This allows longer sampling of each window to check convergence of the results. We take the initial TI windows from the nearest FEP window to facilitate equilibration. Thus we generate forward and backward TI windows from the corresponding FEP windows. Each window is typically equilibrated for 1 ns and sampled for 2 ns. For the LJ interactions, the TI method does not o®er any advantages as it requires as many windows as FEP. Because well-converged results have already been obtained using FEP, we have not repeated the LJ calculations using the TI method.
Results and Discussion
The free energy method described in the last section has been used to calculate the changes in the binding free energy of ShK due to the K18A mutation when it is in complex with the Kv1.1 and Kv1.3 channels. 25 In both complexes, the K18A mutation did not cause any changes in the binding mode. The binding free energy di®erences obtained from the FEP/TI results were in good agreement with both the PMF and experimental results, 25 demonstrating the feasibility and accuracy of this approach for charge mutations where the binding mode is preserved. Because the side chain of arginine is bulkier and the charge is not localized like in lysine, its mutation is more likely to disrupt the binding mode. This has been observed to be the case in both the R29A mutation in ShK and the R14A mutation in HsTx1, the changes in the former being much more substantial. Using these two cases as examples, we investigate whether the FEP/TI calculations can still be used to calculate the changes in the binding free energies when the mutation a®ects the binding mode.
Kv1.1-ShK system
The Kv1.1-ShK[R29A] complex structure obtained from docking and MD simulations is compared to the one obtained directly from the Kv1.x-ShK structure via the R29A mutation in Fig. 2 . The two binding modes are seen to be very di®erent À À À they are separated by more than 45 rotation of the peptide backbone around the channel axis. A more quantitative comparison of the binding modes is provided in Table 1 , where the average distances between the strongly interacting pairs are listed. Here we also include the Kv1.1-ShK results for reference purposes. Apart from the pore inserting lysine (K22), there are no common interactions between the binding modes of Kv1.1-ShK and Kv1.1-ShK[R29A]. All the strong interactions, indicated by the close contact distances in the Kv1.1-ShK complex, are degraded in the Kv1.1-ShK[R29A] complex, and replaced by formation of new contact pairs involving the residues R1, R11 and S10 on the toxin. In contrast, the binding mode of The only noticeable change is that the D361-R11 distance gets shorter. While there is no doubt that Kv1.1-ShK[R29A] has a lower free energy than Kv1.1-ShK[R29A] Ã , the two con¯gurations are likely to be separated by a large free energy barrier, which will hinder any transitions between the two states.
In a FEP/TI calculation of the free energy change due to the R29A mutation, the initial state is the Kv1.1-ShK complex and the¯nal state should be the Kv1.1-ShK [R29A] complex. However, because of the substantial change in the binding mode, it is extremely unlikely that this¯nal state will be attained in the relatively short FEP/ TI calculations. The¯nal state is more likely to be stuck in the Kv1. Fig. 3 give no indication for breaking of these contacts. Thus a FEP/TI calculation of the free energy change due to the R29A mutation in Kv1.1-ShK is not feasible within the typical time frames used in such calculations.
Kv1.1-HsTx1 system
In the case of HsTx1[R14A], the R14A mutation causes little change in the binding mode of the Kv1.1-HsTx1 complex. This is demonstrated in Fig. 4 to overlap very well. This observation is made more quantitative in Table 2 , where the contact distances between the strongly interacting residues forming the binding modes are compared. Apart from the mutated R14, all three charge interactions in the binding mode of Kv1 Table 1 ) from 30 ns MD simulations. Each point is obtained from the average of 0.5 ns of trajectory data. separately. Comparing HsTx1[R14A] with the ShK[R29A] case discussed above, there is no rotation of the toxin and the strongly interacting pairs are preserved after the mutation. The two conditions are clearly linked, and one could use either as an indication for preservation of the binding mode. Here we assume that a mutation may cause some di®erences in weaker interactions, such as Y379-N26 in Kv1.1-HsTx1, but these are small perturbations and do not change the character of the binding mode de¯ned by the strong charge interactions of the basic toxin residues.
It is clear from the discussion of the R29A mutation in the Kv1.1-ShK complex that FEP/TI calculations have little chance of success if the binding mode is not preserved. Using the R14A mutation in the Kv1.1-HsTx1 complex as an example, we now show that the converse is also true, namely, as long as the binding mode is preserved, FEP/TI calculations can be used to predict the free energy change associated with a charge mutation in a protein-ligand complex. Following the thermodynamic cycle in Fig. 1 and Eqs. (2) and (3), we perform the FEP/TI calculations in three stages. The FEP calculations are done for all three stages while the TI calculations are done only for the¯rst and third stages involving the Coulomb interactions. This is because TI does not provide any advantages over FEP for the LJ contributions in the second stage.
Convergence in charge mutations has been an issue in FEP/TI calculations, therefore, we pay special attention to convergence of the results. To illustrate convergence of the FEP calculations, we show the running averages for ÁG i for six windows covering the range from 0 to 1 (Fig. 5) . Flattening of the running averages signals the convergence of the ÁG i values. This is seen to be the case in all examples, and in particular, in discharging/charging of the R14 side chain which is of critical importance. Convergence and sampling problems in free energy calculations are also exposed by large hysteresis e®ects between the forward and backward calculations. To check for hysteresis e®ects, we plot the ÁG i values for each of the three contributions as a function of (Fig. 6) . To facilitate the comparison of the forward and backward results, ÀÁG i is plotted as a function of 1 À for the backward calculations. For each contribution to the free energy change, the backward results are seen to track the forward ones within the statistical°uctuations, indicating minimal hysteresis. The convergence and hysteresis tests in Figs. 5 and 6 give con¯dence that reliable results have been obtained from the FEP calculations for the free energy change due to the R14A mutation on HsTx1.
Convergence of the TI calculations are similarly monitored by plotting the running averages for ÁG against the production time. These are shown in Fig. 7 for discharging/charging of the Arg and Ala side chains in both the forward and backward directions. In both cases, the°attening of running averages signals convergence. Also there is very good overlap between the forward and backward TI calculations for both side chains, indicating that hysteresis e®ects are negligible. Thus the same assertion can also be made for the reliability of the TI calculations.
The results of the FEP/TI calculations are summarized in Table 3 , where the the three contributions to the free energy change in the forward and backward directions as well as their average are listed. It is of interest to compare the FEP and TI calculations for the two Coulomb contributions involving discharging/charging of the R14 and A14 side chains. For the R14 side chain, the average values obtained from FEP and TI are very similar. The same result is obtained for the forward and backward calculations in TI, and there is only a small di®erence between the two calculations in FEP (0.4 kcal/mol), indicating very small hysteresis. We have observed larger hysteresis e®ects when the simulation time is halved. This suggests that the forward-backward hysteresis e®ect could be used to check the su±cency of the simulation time. Because the A14 side chain is neutral overall, the contribution from this term is relatively small, and both methods give very similar results with negligible hysteresis. Finally, the FEP calculations of the LJ contribution are also seen to exhibit minimal hysteresis. The binding free energy changes due to the R14A mutation obtained using the FEP and TI methods are compared to those obtained from the PMF calculations and experiment in Table 4 observation, 39 indicating more than 2.7 kcal/mol gain in Kv1.3/Kv1.1 selectivity margin (we note that the R14A mutation has a negligible e®ect on the binding free energy of HsTx1 to Kv1.3.) 39 Thus, using the FEP/TI method described here, it is possible to calculate accurately the free energy change due to a charge mutation in a protein-ligand complex. Preservation of the binding mode appears to be the only requirement for the success of such calculations.
Conclusion
Charge mutations cause the largest changes in the binding free energy of a ligand, and their accurate calculation has been a challenging problem in the¯eld. Here we have discussed feasibility of such calculations with the FEP/TI methods using the Arg ! Ala mutations in ShK and HsTx1 toxins bound to the Kv1.1 channel as examples. In the case of the Kv1.1-ShK system, the R29A mutation is shown to change the binding mode substantially, which precludes application the FEP/TI methods. In the Kv1.1-HsTx1 system, the binding mode is essentially preserved after the R14A mutation, making the FEP/TI calculations feasible. Using the R14A mutation in HsTx1, we have shown that problems encountered in FEP/TI calculations of charge mutations can be resolved by performing the mutation on the ligand in the binding site and bulk simultaneously and in the same system. A similar result was obtained for the K18A mutation in ShK previously. 25 Because the charge is localized in the Lys side chain and it is less bulky compared to Arg, preservation of the binding mode and convergence of the results are much less of a problem in the Lys ! Ala mutations. The Arg ! Ala mutations discussed here highlight the importance of checking the binding mode before attempting any FEP/TI calculations.
The ShK and HsTx1 toxins are considered here because of their potential use in treatment of autoimmune diseases. Improving their Kv1.3/Kv1.1 selectivity to avoid side e®ects is an important problem in their development as drugs. As shown from FEP/TI calculations, the R14A mutation suggested by the Kv1.1-HsTx1 model improves the Kv1.3/Kv1.1 selectivity margin of HsTx1 by about 3 kcal/mol. Thus construction of accurate complex models and accurate calculation of free energy changes due to mutations can be very helpful in solution of such design problems. Although our discussion was limited to toxin peptides binding to ion channels and their mutations, these methods can be applied to any receptor-ligand system. In particular, they will be very useful in improving a±nity/selectivity properties of drug leads.
